Abstract
Purpose
To examine the diagnostic performance of 18F-fluorothymidine (FLT)-PET/CT of primary and metastatic nodal lesions of gastric cancer by comparing with 18F-fluorodeoxyglucose (FDG)-PET/CT.
Methods
The enrolled study population comprised 17 patients with 17 newly diagnosed gastric cancers who underwent surgery of the primary lesion and regional nodes after both FDG- and FLT-PET/CT scans. Visual detectability of the primary gastric lesions was correlated with pathological factors using the Fisher exact or Mann–Whitney U test. The sensitivity, specificity, and accuracy in detecting nodal lesions were compared between both PET/CT scans using the McNemar exact or χ 2 test.
Results
Fourteen of 17 (82.4%) primary cancers were visualized by both FDG- and FLT-PET/CT scans. Although FDG or FLT visibility was not significantly associated with tumor size (p = 0.16) or histological type (p = 1.00), the 3 nonvisible lesions were pathologically early (T1) cancers. The sensitivity, specificity, and accuracy for detecting nodal metastasis were 44.8% (13/29), 98.7% (164/166), and 90.8% (177/195) for FDG-PET/CT, and 31.0% (9/29), 100% (166/166), and 89.7% (175/195) for FLT-PET/CT, respectively. No significant difference was found between the two scans in sensitivity (p = 0.13), specificity (p = 0.48), or accuracy (p = 1.00).
Conclusion
FLT-PET/CT may have the same diagnostic value as FDG-PET/CT for detection of primary and nodal lesions of gastric cancer.
Similar content being viewed by others
References
Jemal A, Bray F, Center MM, et al. (2008) Global cancer statics. CA Cancer J Clin 61:69–90
Kim HJ, Kim AH, Oh ST, et al. (2005) Gastric cancer staging at multi-detector CT gastrography: comparison of transverse and volumetric CT scanning. Radiology 236:879–885
Fletcher JW, Djulbegovic B, Soares HP, et al. (2008) Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49:480–508
von Schulthess GK, Steinert HC, Hany TF (2006) Integrated PET/CT: current applications and future directions. Radiology 238:405–422
Kim EY, Lee WJ, Choi D, et al. (2011) The value of PET/CT for preoperative staging of advanced gastric cancer: comparison with contrast enhanced CT. Eur J Radiol 79:183–188
Yang QM, Kawamura T, Itoh H, et al. (2008) Is PET-CT suitable for detecting lymph node status for gastric cancer? Hepatogastroenterology 55:782–785
Lim JS, Kim MJ, Yun MJ, et al. (2006) Comparison of CT and 18F-FDG PET for detecting peritoneal metastasis on the evaluation for gastric carcinoma. Korean J Radiol 7:249–256
Shields AF, Grierson JR, Dohmen BM, et al. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4:1334–1336
Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43:1210–1217
Bading JR, Shields AF (2008) Imaging of cell proliferation: status and prospects. J Nucl Med 49:64s–80s
Herrmann K, Ott K, Buck AK, et al. (2007) Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med 48:1945–1950
Kameyama R, Yamamoto Y, Izuishi K, et al. (2009) Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 36:382–388
Zhou M, Wang C, Hu S, et al. (2013) 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging. Nucl Med Commun 34:694–700
Małkowski B, Staniuk T, Srutek E, et al. (2013) (18)F-FLT PET/CT in Patients with Gastric Carcinoma. Gastroenterol Res Pract 2013:696423
Staniuk T, Zegarski W, Malkowski B, et al. (2013) Evaluation of FLT-PET/CT usefulness in diagnosis and qualification for surgical treatment of gastric cancer. Cotemp Oncol 17:165–170
Oh SJ, Mosdzianowski C, Chi DY, et al. (2004) Fully automated synthesis system of 3′-deoxy-3′-[18F]fluorothymidine. Nucl Med Biol 31:803–809
Edge SB, Byrd DR, Compton CC, et al. (eds) (2010) American joint committee on cancer. AJCC cancer staging handbook, 7th edn. New York: Springer
Stahl A, Ott K, Weber WA, et al. (2013) FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 30:288–295
Hamilton SR, Aaltonen LA (2000) Tumors of the stomach. WHO classification of tumors. In: Hamilton SR, Aaltonen LA (eds) Pathology and genetics of tumors of the digestive system. Lyon: IARC Press, pp 38–52
Tian J, Yang X, Yu L, et al. (2008) A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3′-deoxy-3′-18F-fluorothymidine and 18F-FDG. J Nucl Med 49:186–194
Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174
Smyth EC, Shah MA (2011) Role of 18F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies. World J Gastroenterol 17:5059–5074
Wu CX, Zhu ZH (2014) Diagnosis and evaluation of gastric cancer by positron emission tomography. World J Gastroenterol 20:4574–4585
Filik M, Kir KM, Aksel B, et al. (2015) The Role of 18F-FDG PET/CT in the primary staging of gastric cancer. Mol Imaging Radionucl Ther 24:15–20
Ha TK, Choi YY, Song SY, Kwon SJ (2011) F18-fluorodeoxyglucose-positron emission tomography and computed tomography is not accurate in preoperative staging of gastric cancer. J Korean Surg Soc 81:104–110
Alakus H, Batur M, Schmidt M, et al. (2010) Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun 31:532–538
Takebayashi R, Izuishi K, Yamamoto Y, et al. (2013) [18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer. J Exp Clin Cancer Res 32:34
Nakajo M, Nakajo M, Kajiya Y, et al. (2013) Diagnostic performance of 18F-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with 18F-fluorodeoxyglucose PET/CT. Eur J Nucl Med Mol Imaging 40:1223–1232
Been LB, Suurmeijer AJ, Cobben DC, et al. (2004) [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 31:1659–1672
Kubota K, Kubota R, Yamada S (1993) FDG accumulation in tumor tissue. J Nucl Med 34:419–421
Higashi K, Clavo AC, Wahl RL (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34:414–419
van Westreenen HL, Cobben DC, Jager PL, et al. (2005) Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer. J Nucl Med 46:400–404
Herrmann K, Erkan M, Dobritz M, et al. (2012) Comparison of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur J Nucl Med Mol Imaging 39:846–851
Ott K, Herrmann K, Schuster T, et al. (2011) Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol 18:3316–3323
Pio BS, Park CK, Pietras R, et al. (2006) Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8:36–42
Kishino T, Hoshikawa H, Nishiyama Y, Yamamoto Y, Mori N (2012) Usefulness of 3′-deoxy-3′- 18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer. J Nucl Med 53:1521–1527
Graf N, Herrmann K, Numberger B, et al. (2013) [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner. Eur J Nucl Med Mol Imaging 40:34–43
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict interest.
Animal rights statements
This article does not contain any studies with animals performed by any of the authors.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individuals participants included in the study.
Rights and permissions
About this article
Cite this article
Nakajo, M., Kajiya, Y., Tani, A. et al. FLT-PET/CT diagnosis of primary and metastatic nodal lesions of gastric cancer: comparison with FDG-PET/CT. Abdom Radiol 41, 1891–1898 (2016). https://doi.org/10.1007/s00261-016-0788-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-016-0788-6